ACM
SYRS

Adalta Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Adalta Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,593
Closed -$190K – 80
2018
Q3 		$190K Hold
1,593
– – 0.14% 75
2018
Q2 		$163K Buy
1,593
+78
+5% +$9.66K 0.12% 77
2018
Q1 		$197K Buy
1,515
+377
+33% +$41.2K 0.15% 70
2017
Q4 		$111K Buy
+1,138
New +$153K 0.08% 71

Other funds holding SYRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adalta Capital Management's SYRS Position: Q4 2018 in Review

Adalta Capital Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q4 2018, closing a stake of 1,593 shares — an estimated $190K sold.

Adalta Capital Management first reported a position in SYRS in Q4 2017 and held it in 4 quarters. The position peaked at $197K in Q1 2018. 68 funds tracked by Wall St. Rank hold SYRS as of Q4 2018.

  • Adalta Capital Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Adalta Capital Management sold 1,593 Syros Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $190K.
  • Adalta Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
  • Adalta Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $197K in Q1 2018.
  • 68 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Adalta Capital Management's 13F filing for Q4 2018, filed 15 Feb 2019.